BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210113
DTEND;VALUE=DATE:20210115
DTSTAMP:20260515T140656
CREATED:20200910T124837Z
LAST-MODIFIED:20201015T100412Z
UID:26969-1610496000-1610668799@www.pharmajournalist.com
SUMMARY:Pre-Filled Syringes and Injectable Drug Devices 2021
DESCRIPTION:Device design\, regulatory and strategic pathways for parenteral drug delivery \nSMi is proud to present the 13th Annual Pre-Filled Syringes Conference on 13th and 14th January 2021. \nThe pre-filled syringes industry is growing at an exponential rate. With increasing demand for self-administration\, a rise in biologics\, large-volume delivery and the delayed EU MDR at the forefront of the field\, SMi’s 13th annual event will bring you the key insights you need to grow and enhance your pre-filled syringes portfolio and discover what the future holds for the PFS and combination products industry. \nTopics of discussion will include the latest updates on the EU MDR and Article 117\, advances in novel drug products and biologics\, parenteral packaging for pre-filled syringes\, innovations in device design and platforms for combination products\, lifecycle management and much more… \n \nThe two-day agenda offers you peer-to-peer networking with Global Product Managers\, Senior PFS Engineers\, Device Testing Managers\, Heads of Late-Stage PFS Development and many more. \nAs Europe’s first Pre-Filled Syringes Conference of 2021\, this event is not to be missed. We look forward to welcoming you to the conference in January. \nBENEFITS OF ATTENDING:  \n\nEngage with senior industry opinion leaders presenting their experiences and case studies in innovative device design and advanced drug product formulation\nGain insights from notified body and competent authority representatives addressing key regulatory requirements\nUnderstand how to optimize your lifecycle management strategy for a commercially successful device\nExplore and benchmark against industry advances in device design through case studies and real-world examples\n\nView the full agenda and speaker line-up online: www.pre-filled-syringes.com/pjwl \nPlus\, pre-conference workshops will be taking place on 12th January : \nWorkshop A: Digital Health – What are the real-world opportunities and potential barriers to adoption?\nWorkshop Leader: Andrew Dundon\, Founder\, PharMechceutics Ltd\n08.30 – 12.00  \nWorkshop B: Challenges and Drivers for Development of Long Acting Injectables\nWorkshop Leader: Joël Richard\, Chief Development Officer\, MedinCell\n13.00 – 17.00 \nEARLY-BIRD RATES: \n\nBOOK BY 30TH SEPTEMBER AND SAVE £400\nBOOK BY 30TH OCTOBER AND SAVE £200\nBOOK BY 30TH NOVEMBER AND SAVE £100\n\nRegistrations can be made on the event website at: www.pre-filled-syringes.com/pjwl \nChairs for 2020: \n\nBjørg Kaae Hunter\, Department Manager\, RA CMC & Device; RA NextGen Drug-Device\,\nNovo Nordisk\nAlphons Fakler\, Head Medical Device Risk Management\, Novartis\n\nFeatured speakers:  \n\nBrian Holly\, Head of Human Factors\, Devices Centre of Excellence\, Pfizer \nDaniel Latham\, Head Device Development & LCM\, Novartis \nRene Holm\, Head and Scientifi c Director\, Drug Product Development\, Liquids and Parenterals\, Janssen\nStefano Martini\, Responsible for Special Programs\, Medical Devices Development\, Sanofi \nSarah Tang\, Regulatory Affairs Manager\, Devices Division\, MHRA \nAbha Raveau violette\, Device Manager\, AstraZeneca \nVikas Jaitely\, Director\, Global Regulatory Affairs Transitional Medicine and Devices\, Merck \nJulia Frese\, Director\, TÜV SÜD\nClemens Günther\, Director\, Senior Expert Nonclinical Safety\, Bayer \nJonathan Sutch\, Technical Specialist\, BSI\n\nAdditional Contact Info: \nT: +44 (0)20 7827 6088\nE: hsidhu@smi-online.co.uk\nFollow us:  @SMiPharm #PFSSMi
URL:https://www.pharmajournalist.com/event/pre-filled-syringes-and-injectable-drug-devices-2021/
LOCATION:Virtual Event
ORGANIZER;CN="SMi Group":MAILTO:hsidhu@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210120
DTEND;VALUE=DATE:20210122
DTSTAMP:20260515T140656
CREATED:20201117T084847Z
LAST-MODIFIED:20201117T084847Z
UID:27957-1611100800-1611273599@www.pharmajournalist.com
SUMMARY:Onco Cell Therapy Global
DESCRIPTION:Following the success of our first digital event in July with the likes of Carl June leading the keynote\, the Onco Cell Therapy Summit is returning in its most interactive form ever with 20+ panel conversations\, townhall meetings\, roundtable sessions and coffee break style networking. \n \nThe Global Onco Cell Therapy Summit is an online event\, 20th – 21st January 2021\, that provides a platform for information sharing to enable the discovery\, translation and commercialization of cell therapies in oncology by connecting senior representatives in pharma\, biotechs and academia. The summit will address the research\, regulatory\, logistical and technical challenges that are holding back the field. \nDelve into how thought leaders in cell therapy are addressing threats and opportunities to bring effective therapies to the market through: \n\nMeeting efficacies and safety targets as well as the scale of demands.\nDiscovering the latest advances in the journey towards effective allogeneic and solid tumor targeting therapies.\nOvercoming the challenging in scale up and automation of manufacturing\nRound table discussions on vectors and the promise of non-viral approaches.\nReimbursement strategies and their link to the latest developments in safety trials and regulatory standards\n\nWhilst bringing together the key decision makers for oncological cell therapies\, this year’s summit will have an added focus on the data releases and mergers that are driving the surge of interest in harnessing alternative cell therapies in cancer treatments. \nNew for 2020 | Pre-event sessions: \n25th Nov | Manufacturing roundtable | FREE to attend \n15th Dec | ASH Review | FREE to attend \n19th Jan | NK Day | Registrants only \nVisit the website www.oncocelltherapyglobal.com for more details and to view the full agenda. (link to https://go.kisacoresearch.com/l/678123/2020-11-16/4r1xv). Don’t forget as a reader of Pharma Journalist\, quote PJ10 for a 10% discount.
URL:https://www.pharmajournalist.com/event/onco-cell-therapy-global/
LOCATION:Virtual Event
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210126
DTEND;VALUE=DATE:20210129
DTSTAMP:20260515T140656
CREATED:20201027T084532Z
LAST-MODIFIED:20201027T084532Z
UID:27681-1611619200-1611878399@www.pharmajournalist.com
SUMMARY:TGFβ for Immuno-Oncology Drug Development Summit
DESCRIPTION:The world of TGFβ is at a tipping point within industry\, for an explosion of data to come.  \nExploring the wide array of approaches being utilized in pharma\, biotech\, and academia\, the TGFβ for Immuno-Oncology Drug Development Summit is the ONLY industry-led event dedicated exclusively to exploring TGF-beta’s role in cancer therapeutics. This 3-day summit is your definitive meeting to delve into the core challenges of this complex target.  \n \nDon’t miss out on your chance to deepen your understanding of cell signaling mechanisms\, change your view of the tumor microenvironment\, and prepare your candidates for the clinic to ensure patient safety.   \nJoin your peers this year to: \n\nHear from Scholar Rock on the selective inhibition of TGFβ1 activation with SRK-181\, their phase 1 candidate  \nDiscover the latest on Bintrafusp Alfa clinical trials from James Gulley at NCI\, and Clinical Development from Yan Lan at EMD Serono \n\n\nExplore the mechanism of action data from Novartis on their anti-transforming growth factor-beta antibody XOMA089 \nGet involved in Takeda\, Scholar Rock\, Oncotelic\, and Sanofi’s debate the best TGF-beta isoform to target\, combination vs monotherapy approaches\, and the winning therapeutic approach  \nContrast Small Molecule vs Antibody approaches to utilizing Integrin Inhibition with presentations from Morphic Therapeutic and Venn Therapeutics  \n\n To know more about TGFβ for Immuno-Oncology Drug Development Summit please click here.
URL:https://www.pharmajournalist.com/event/tgf%ce%b2-for-immuno-oncology-drug-development-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210126
DTEND;VALUE=DATE:20210129
DTSTAMP:20260515T140656
CREATED:20201204T104141Z
LAST-MODIFIED:20201204T104141Z
UID:28158-1611619200-1611878399@www.pharmajournalist.com
SUMMARY:4th Antigen Specific Immune Tolerance Summit (ASIT)
DESCRIPTION:The 4th Antigen Specific Immune Tolerance Digital Summit (ASIT) brings together industry representatives from the fields of autoimmunity\, allergy\, immuno-oncology and transplantation to tackle the complexities behind autoimmune disorders head on. With momentum building for antigen specific immunotherapies\, ASIT 2021 will be the only antigen-specific summit offering thought-leading content to drive the field towards a more precise and ethical antigen-specific approach to drug development. \n \nThis is the industry’s definitive antigen specific drug development forum. \nAcross 3 packed days\, thought leaders from Novartis\, ImCyse\, Harvard Medical School\, Toleranzia\, Toralgen will reveal insight\, data\, and lessons learned from the last 12 months to enable you to hurdle the roadblocks preventing the development of clinically safe and effective antigen-specific immunotherapies for autoimmune and immune mediated disorders. \nTo know more about 4th Antigen Specific Immune Tolerance Summit (ASIT) please click here.
URL:https://www.pharmajournalist.com/event/4th-antigen-specific-immune-tolerance-summit-asit/
LOCATION:Digital Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR